AveXis (AVXS) Receives Media Impact Rating of 0.18
Media stories about AveXis (NASDAQ:AVXS) have trended somewhat positive recently, Accern reports. The research firm ranks the sentiment of news coverage by analyzing more than twenty million news and blog sources in real-time. Accern ranks coverage of public companies on a scale of negative one to one, with scores nearest to one being the most favorable. AveXis earned a news impact score of 0.18 on Accern’s scale. Accern also gave media stories about the company an impact score of 44.6817658277533 out of 100, indicating that recent news coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the media stories that may have effected Accern Sentiment’s scoring:
- Why A Gene Therapy Pioneer Is Raising Concerns About Treatments He Championed (finance.yahoo.com)
- AveXis Inc (AVXS) VP Sells $236,260.00 in Stock (americanbankingnews.com)
- AveXis Inc (AVXS) Insider Sells $1,771,050.00 in Stock (americanbankingnews.com)
- Q1 2018 Earnings Estimate for AveXis Inc (AVXS) Issued By Jefferies Group (americanbankingnews.com)
- AveXis Inc (AVXS) Receives Consensus Rating of “Buy” from Analysts (americanbankingnews.com)
AveXis (NASDAQ AVXS) opened at $106.19 on Friday. The stock has a market capitalization of $4,249.45, a P/E ratio of -19.03 and a beta of 2.10. AveXis has a 12-month low of $53.94 and a 12-month high of $128.00.
A number of brokerages have recently commented on AVXS. William Blair reissued a “buy” rating on shares of AveXis in a research report on Tuesday, January 30th. BMO Capital Markets reaffirmed a “buy” rating and issued a $150.00 price objective on shares of AveXis in a research report on Thursday, January 18th. Credit Suisse Group started coverage on AveXis in a research report on Wednesday, January 17th. They issued an “outperform” rating and a $134.00 price objective on the stock. Royal Bank of Canada reaffirmed a “hold” rating and issued a $92.00 price objective on shares of AveXis in a research report on Tuesday, January 9th. Finally, Zacks Investment Research raised AveXis from a “sell” rating to a “hold” rating in a research report on Tuesday, January 9th. Three research analysts have rated the stock with a sell rating, four have assigned a hold rating and fourteen have assigned a buy rating to the company’s stock. AveXis has a consensus rating of “Buy” and an average target price of $113.89.
In other AveXis news, VP Andrew F. Knudten sold 2,000 shares of the business’s stock in a transaction on Monday, December 4th. The shares were sold at an average price of $94.48, for a total transaction of $188,960.00. Following the completion of the sale, the vice president now directly owns 7,000 shares in the company, valued at approximately $661,360. The sale was disclosed in a document filed with the SEC, which is available through this link. Also, VP Sukumar Nagendran sold 1,780 shares of the business’s stock in a transaction on Friday, December 1st. The shares were sold at an average price of $94.77, for a total transaction of $168,690.60. Following the sale, the vice president now owns 1,780 shares of the company’s stock, valued at $168,690.60. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 57,560 shares of company stock valued at $6,160,062. Company insiders own 18.60% of the company’s stock.
ILLEGAL ACTIVITY WARNING: “AveXis (AVXS) Receives Media Impact Rating of 0.18” was published by Watch List News and is owned by of Watch List News. If you are viewing this piece on another website, it was copied illegally and republished in violation of United States and international trademark & copyright law. The original version of this piece can be accessed at https://www.watchlistnews.com/avexis-avxs-receives-media-impact-rating-of-0-18/1854841.html.
AveXis, Inc is a clinical-stage gene therapy company. The Company operates through the developing and commercializing gene therapy treatments for patients suffering from neurological genetic diseases segment. The Company’s product candidate, AVXS-101, is its gene therapy product candidate that is in a Phase I clinical trial for the treatment of spinal muscular atrophy (SMA) Type 1, which is a genetic disorder characterized by motor neuron loss and associated muscle deterioration.
Receive News & Ratings for AveXis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AveXis and related companies with MarketBeat.com's FREE daily email newsletter.